Post by
Eoganacht on Aug 04, 2023 2:16pm
Theralase's ACT doesn't need to be the cure for cancer
In a recent interview Roger said:
"The latest data that Theralase has put out - we had a 66 complete response rate at any point in time with 33 at 15 months. So dramatically higher than what's already been approved. So we think it bodes well for the future of the company. And it bodes well for value of the organization. Hopefully it bodes well for the shareholders and the stakeholders in the company as well."
Halfway through the phase 2, TLD1433 PDT has proven itself to be a better solution than the approved treatments for BCG-unresponsive NMIBC in terms of safety, efficacy and number of treatments.
15 month CR rates could be 10% or more higher by the end of the trial (43%+ CR).
I think there is no doubt whatsoever that TLD1433 PDT will benefit bladder cancer patients with very little down side and will be a valuable addition to the anti-cancer tools available.
And that should be all that is needed for BTD, AA and a dramatic rise in the stock price. Big pharmas should be tripping over each other to acquire Theralase.
I don't get why this is not happening.
In the current trial TLD1433 PDT is being used on the most difficult to treat kind of NMIBC - high-grade BCG-unresponsive NMIBC with or without CIS. If it proves itself in this trial it could go head to head against BCG as a first line treatment and also be trialed for MIBC.
TLD1433 PDT could end up benefiting patients with all the varieties of bladder cancer - as a standalone treatment and/or an adjunct to other treatments.
And if it works with bladder cancer, there is a high probability it could be adapted for use against NSCLC, GBM, melanoma, colon, breast, pancreatis, esophageal etc. It doesn't have to totally cure any of these cancer types - just be of benefit to the patient - destroy tumours, or just shrink them and encourage the patient's own immune system to kick in.
And there is all the other research of Dr. McFarland waiting in the wings. All of the more potent ruthenium and osmium based photosensitizers that Theralase has rights to.
So why are we sitting at 27 cents with no money in the till?
Comment by
N0taP00p on Aug 04, 2023 3:21pm
Very well said! It just doesn't make sense. Hopefully, just a matter of weeks.
Comment by
skys1 on Aug 04, 2023 4:12pm
Great post Eoganacht !!! The fact that several members of the Big Pharma community havn't already made a move on TLT is very surpriseing considering it is head & sholders it's competition. All will happen in due time.
Comment by
Legit62 on Aug 04, 2023 4:19pm
Skys1 i agree, i feel the BTD and AA takes the risk out IMO
Comment by
skys1 on Aug 04, 2023 4:25pm
Agree Legit, After BTD & AA, a bidding war could ensue.
Comment by
ggrellette on Aug 04, 2023 5:03pm
Designations will definitely open many eyes and investors wallets. The biggest event those designations will do is bring big pharmas to the table. Yep JV partnerships. We all know when that will happen is when the volume suddenly increases substantially.